

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
03 February 2022 (03.02.2022)



(10) International Publication Number
WO 2022/023538 A3

(51) International Patent Classification:
C07K 16/28 (2006.01) A61P 35/00 (2006.01)
C07K 14/81 (2006.01)

(21) International Application Number:
PCT/EP2021/071417

(22) International Filing Date:
30 July 2021 (30.07.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/059,026 30 July 2020 (30.07.2020) US
63/059,037 30 July 2020 (30.07.2020) US

(71) Applicant: AVACTA LIFE SCIENCES LIMITED
[GB/GB]; Unit 20 Ash Way, Thorp Arch Estate, Wetherby
LS23 7FA (GB).

(72) Inventors: JENKINS, Emma; 47 Brook Road, Stansted
Essex CM24 8BB (GB). ADAM, Estelle; 42b Bearton
Road, Hitchin Hertfordshire SG5 1UE (GB). STANLEY,
Emma; 65 West Hill, Hitchin Hertfordshire SG5 2HY
(GB). BASRAN, Amrik; 42 Beaumont Road, Cambridge
Cambridgeshire CB1 8PY (GB). VINCENT, Matthew P.;
12 Quimby Lane, Amesbury, Massachusetts 01913-5512
(US).

(74) Agent: HOFFMANN EITLE PATENT- UND
RECHTSANWÄLTE PARTMBB, ASSOCIATION
NO. 151; Arabellastraße 30, 81925 Munich (DE).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,

SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(88) Date of publication of the international search report:
10 March 2022 (10.03.2022)

(54) Title: SERUM HALF-LIFE EXTENDED PD-L1 INHIBITORY POLYPEPTIDES




FIG. 1A

(57) Abstract: Provided herein, in some embodiments, are fusion proteins comprising recombinantly engineered variant of stefin polypeptide (an AFFIMER® polypeptide) that binds to PD-L1 and a polypeptide that binds to human serum albumin (HSA). Also provided herein, in some embodiments, are compositions containing the fusion proteins, methods of using the fusion proteins, and methods of producing the fusion proteins.

WO 2022/023538 A3